α-Pyrrolidinoisohexanophenone hydrochloride cas: 2705245-60-7

CAS NO: 2705245-60-7
α-Pyrrolidinoisohexanophenone hydrochloride
Description Review
Description



α-Pyrrolidinoisohexanophenone: This part of the name indicates a molecular structure that combines a pyrrolidine ring with an isohexanophenone moiety. The pyrrolidine ring is a saturated heterocycle with one nitrogen atom and four carbon atoms. The isohexanophenone suggests a branched ketone structure connected to a benzene ring. Hydrochloride Form: As a hydrochloride salt, this compound has enhanced water solubility, which is often desired for pharmaceutical applications. The hydrochloride form is commonly used in medicinal chemistry to improve drug stability and bioavailability. Potential Uses and Effects Synthetic Stimulant: Compounds like α-Pyrrolidinoisohexanophenone are often researched for their stimulant effects. These effects can include increased alertness, energy, and euphoria, but they also pose risks of adverse effects, especially at high doses or with prolonged use. Research Interest: Chemists and pharmacologists might study this compound for its potential therapeutic uses or to understand its mechanism of action. It can also be a subject of toxicological studies due to the risks associated with synthetic stimulants. Safety and Regulation Controlled Substance: Many synthetic stimulants are regulated under various drug control laws. The legal status of α-Pyrrolidinoisohexanophenone hydrochloride would depend on its specific pharmacological profile and the jurisdiction in question. Toxicology: Understanding the toxicological profile of such compounds is crucial for assessing their safety. This includes studying their potential for abuse, addictive properties, and long-term health effects. Pharmaceutical Context Pharmacodynamics and Pharmacokinetics: These studies would focus on how the drug affects the body (pharmacodynamics) and how the body processes the drug (pharmacokinetics). This includes absorption, distribution, metabolism, and excretion. Potential Therapeutic Applications: If the compound has unique properties, it might be investigated for specific therapeutic uses. However, the development of any pharmaceutical agent involves rigorous testing and regulatory approval processes. Research and Synthesis Synthetic Pathways: Chemists would be interested in the methods to synthesize this compound, optimizing yield, purity, and cost-effectiveness. Analogues and Derivatives: Research might also focus on developing analogues or derivatives of α-Pyrrolidinoisohexanophenone to explore different pharmacological profiles or improve safety and efficacy. Advanced Studies Molecular Interactions and Receptors: Studies might explore how the compound interacts with specific receptors or enzymes in the body, contributing to its stimulant effects. Comparative Studies: Comparing this compound with other similar stimulants can provide insights into structure-activity relationships, aiding in the design of better pharmaceutical agents. In summary, α-Pyrrolidinoisohexanophenone hydrochloride is a compound of interest in medicinal chemistry and pharmacology, with potential applications as a synthetic stimulant. However, its use and research are likely to be heavily influenced by safety concerns, legal status, and the ongoing efforts to understand and mitigate the risks associated with synthetic stimulants.









  1. α-Pyrrolidinoisohexanophenone structure,
  2. Pyrrolidine ring chemistry,
  3. Isohexanophenone properties,
  4. Hydrochloride salt in pharmaceuticals,
  5. Water solubility of stimulants,
  6. Synthetic stimulant effects,
  7. α-Pyrrolidinoisohexanophenone pharmacology,
  8. Toxicology of synthetic stimulants,
  9. Legal status of α-Pyrrolidinoisohexanophenone,
  10. Pharmacodynamics of stimulants,
  11. Pharmacokinetics in drug development,
  12. Therapeutic applications of α-Pyrrolidinoisohexanophenone,
  13. Synthetic pathways in medicinal chemistry,
  14. Analogues of α-Pyrrolidinoisohexanophenone,
  15. Molecular interactions of stimulants,
  16. Comparative studies in pharmacology.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code